ProKidney Corp. (NASDAQ: PROK) is a Healthcare company (Biotechnology) with a market capitalization of $370M. The Maz Rating grades it against the other companies in its sector.
ProKidney Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.10, ProKidney Corp. trades at 479.4x sales. Over the last twelve months it generated about $771493 of revenue and a net loss of $201M. It runs a gross margin of -12872.9%, an operating margin of -24830.3% and a net margin of -13326.7%. It shows return on equity of 10.8%, return on invested capital of -104.3% and a free cash flow yield of -45.4%. On the balance sheet: a debt-to-equity ratio of -0.00 and a current ratio of 5.04. Over the past 52 weeks the share price ranged from $0.87 to $2.65, with a beta of 1.90.
ProKidney Corp. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 6 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, ProKidney Corp. (PROK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.30% / 30% · (Cash+Inv) / Mkt Cap (36m) 19.4% / 30% · Interest income / Revenue 879.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.30% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 19.4% / 33% · Receivables / Mkt Cap (36m) 0.09% / 49% · Interest income / Revenue 879.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.30% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 19.4% / 33.33% · Receivables / Mkt Cap (24m) 0.09% / 33.33% · Interest income / Revenue 879.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.20% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 75.2% / 33.33% · Receivables / Avg Assets (4Q) 0.34% / 33.33% · Interest income / Revenue 879.3% / 5% | Fail |
| FTSE | Debt / Total Assets 1.05% / 33.33% · (Cash+ST Inv) / Total Assets 67.5% / 33.33% · (Cash+Recv) / Total Assets 67.8% / 33.33% · Interest income / Revenue 879.3% / 5% | Fail |
No. As of September 2026, ProKidney Corp. (PROK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. ProKidney Corp. is over the AAOIFI limit on Interest income / Revenue.
About 879.3% of each dividend: ProKidney Corp.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.